Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD known ✓ | Q03181 | 11/20 | 0.47 |
| ▸ | PPARG | P37231 | 17/20 | 0.80 |
| ▸ | PPARA | Q07869 | 17/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6739285 | 0.90 | PPARG (0.68) | PPARGPPARAPPARD | |
| SCHEMBL6737276 | 0.89 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL6731283 | 0.82 | PPARG (0.82) | PPARGPPARAPPARD | |
| SCHEMBL6731137 | 0.82 | PPARG (0.86) | PPARGPPARAPPARD | |
| SCHEMBL6738494 | 0.82 | PPARG (0.84) | PPARGPPARAPPARD | |
| SCHEMBL6738500 | 0.82 | PPARG (0.84) | PPARGPPARAPPARD | |
| SCHEMBL6731054 | 0.81 | PPARG (0.84) | PPARGPPARAPPARD | |
| SCHEMBL6735927 | 0.81 | PPARG (0.83) | PPARGPPARAPPARD | |
| SCHEMBL6735203 | 0.81 | PPARG (0.85) | PPARGPPARAPPARD | |
| SCHEMBL6734280 | 0.80 | PPARG (0.82) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683111-B2 | SUCH AS 2-ETHOXY-3-(4-(2-XANTHEN-9-YLIDENE-ETHOXY)-PHENYL)-PROPIONIC ACID; FOR TREATING CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; TREATMENT OF DIABETES/OBESITY | NOVO NORDISK A/S (DK) | 2004-01-27 | — | — | US | disclosed |
| US-RE37886-E1 | 1-(1,2-Disubstituted piperidinyl)-4-substituted piperazine derivatives | JANSSEN PHARMACEUTICALS, N.V. (BE) | 2002-10-15 | — | — | US | disclosed |
| US-20020115654-A1 | New compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | disclosed |
| US-6353018-B1 | Compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2002-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115654-A1 | New compounds, their preparation and use | PPARG, PPARD, PPARA | PPARD 2/4885PPARG 1/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.